Global Ocular Drug Delivery Technology

Ocular Drug Delivery Technology Comprehensive Study by Type (Biodegradable Ocular Drug Delivery Technology, Non-Biodegradable Ocular Drug Delivery Technology), Application (Hospitals, Ambulatory Surgical Centers, Ophthalmic Clinics, Homecare Settings), Technology (Topical, Iontophoresis, Ocular insert, Intraocular implants, Others), Disease Indication (Cataract Surgery, Allergic Conjunctivitis, Retinal Vein Occlusion, Bulbar Conjunctiva, Sympathetic Ophthalmia, Others) Players and Region - Global Market Outlook to 2026

Ocular Drug Delivery Technology Market by XX Submarkets | Forecast Years 2022-2027  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Industry Background:
Drug delivery refers to methodologies, technologies, and systems for the targeted delivery and controlled release of therapeutic agents. Many drugs, discovered during advanced biology strategies, have unacceptable side effects due to their interaction with health issues. Drug delivery systems limit those side effects by targeting only the diseased part. Ocular drug delivery technology deals with eyes or parts of eyes. The growing aging population globally has more and more eye-related diseases so, demand for ocular drug delivery is rising.This growth is primarily driven by Rising Old Age Population with Eye Diseases, Low Bioavailability of Drugs in Conventional Ocular Therapies and Demand Because of its Ability to Treat Previously Uncurable Diseases.

Globally, a noticeable market trend is evident Increases Use in Treating Diseases Like Glaucoma, Diabetic Retinotherapy, Dry Eye Syndrome, etc.. Major Players, such as Ocular Therapeutix, Inc. (United States), Alimera Sciences (United States), Allergan plc (Ireland), Bausch Health Cos. (United States), EyeGate Pharma (United States), Santen Pharmaceutical Co. Ltd (Japan), Graybug Vision Inc. (United States), Clearside Biomedical (United States), Envisia Therapeutics (United States) and Taiwan Liposome Company (United States) etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years.

On 04 March 2021, Ocular Theraputix, a leading company in ocular drug delivery; announced FDA acceptance of supplemental new drug application for dexamethasone ophthalmic insert (DEXTENZA) for the treatment of ocular itching associated with allergic conjunctivitis. DEXTENZA is now FDA approved for the treatment of ocular inflammation and pain after surgery.

Market Drivers
  • Rising Old Age Population with Eye Diseases
  • Low Bioavailability of Drugs in Conventional Ocular Therapies
  • Demand Because of its Ability to Treat Previously Uncurable Diseases

Market Trend
  • Increases Use in Treating Diseases Like Glaucoma, Diabetic Retinotherapy, Dry Eye Syndrome, etc.

Restraints
  • High-Cost Investment Involved the Treatment with Ocular Drug Delivery Technology

Opportunities
Innovation in Nanotechnology is Benefitting the Innovation in Ocular Drug Delivery Technology and The rise in the Development of Eye Care Infrastructure will boost the Ocular Drug Delivery Technology
Challenges
High R&D Cost Associated with Ocular Drug Delivery Technology and Lack of Enough Skilled Professionals in The Market

AMA Research follow a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcase the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyse the products and services offered by multiple players competing to increase their market share and presence.

Customization in the Report
AMA Research features not only specific market forecasts, but also include significant value-added commentary on:
- Market Trends
- Technological Trends and Innovations
- Market Maturity Indicators
- Growth Drivers and Constraints
- New Entrants into the Market & Entry/Exit Barriers
- To Seize Powerful Market Opportunities
- Identify Key Business Segments, Market Proposition & Gap Analysis

Against this Challenging Backdrop, Ocular Drug Delivery Technology Study Sheds Light on
— The Ocular Drug Delivery Technology Market status quo and key characteristics. To end this, Analyst at AMA organize and took survey of the Ocular Drug Delivery Technology industry Players. The resultant snapshot serves as a basis for understanding why and how the industry can be expected to change.
— Where Ocular Drug Delivery Technology industry is heading and what are the top priorities. Insights are drawn from financial analysis, the survey and interviews with key executives and industry experts.
— How every company in this diverse set of Players can best navigate the emerging competition landscape and follow a strategy that helps them position to hold value they currently claim, or capture the new addressable opportunity.

Report Objectives / Segmentation Covered

By Type
  • Biodegradable Ocular Drug Delivery Technology
  • Non-Biodegradable Ocular Drug Delivery Technology
By Application
  • Hospitals
  • Ambulatory Surgical Centers
  • Ophthalmic Clinics
  • Homecare Settings
By Technology
  • Topical
  • Iontophoresis
  • Ocular insert
  • Intraocular implants
  • Others

By Disease Indication
  • Cataract Surgery
  • Allergic Conjunctivitis
  • Retinal Vein Occlusion
  • Bulbar Conjunctiva
  • Sympathetic Ophthalmia
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Rising Old Age Population with Eye Diseases
      • 3.2.2. Low Bioavailability of Drugs in Conventional Ocular Therapies
      • 3.2.3. Demand Because of its Ability to Treat Previously Uncurable Diseases
    • 3.3. Market Challenges
      • 3.3.1. High R&D Cost Associated with Ocular Drug Delivery Technology
      • 3.3.2. Lack of Enough Skilled Professionals in The Market
    • 3.4. Market Trends
      • 3.4.1. Increases Use in Treating Diseases Like Glaucoma, Diabetic Retinotherapy, Dry Eye Syndrome, etc.
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Ocular Drug Delivery Technology, by Type, Application, Technology, Disease Indication and Region (value) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global Ocular Drug Delivery Technology (Value)
      • 5.2.1. Global Ocular Drug Delivery Technology by: Type (Value)
        • 5.2.1.1. Biodegradable Ocular Drug Delivery Technology
        • 5.2.1.2. Non-Biodegradable Ocular Drug Delivery Technology
      • 5.2.2. Global Ocular Drug Delivery Technology by: Application (Value)
        • 5.2.2.1. Hospitals
        • 5.2.2.2. Ambulatory Surgical Centers
        • 5.2.2.3. Ophthalmic Clinics
        • 5.2.2.4. Homecare Settings
      • 5.2.3. Global Ocular Drug Delivery Technology by: Technology (Value)
        • 5.2.3.1. Topical
        • 5.2.3.2. Iontophoresis
        • 5.2.3.3. Ocular insert
        • 5.2.3.4. Intraocular implants
        • 5.2.3.5. Others
      • 5.2.4. Global Ocular Drug Delivery Technology by: Disease Indication (Value)
        • 5.2.4.1. Cataract Surgery
        • 5.2.4.2. Allergic Conjunctivitis
        • 5.2.4.3. Retinal Vein Occlusion
        • 5.2.4.4. Bulbar Conjunctiva
        • 5.2.4.5. Sympathetic Ophthalmia
        • 5.2.4.6. Others
      • 5.2.5. Global Ocular Drug Delivery Technology Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Ocular Drug Delivery Technology: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Ocular Therapeutix, Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Alimera Sciences (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Allergan plc (Ireland)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Bausch Health Cos. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. EyeGate Pharma (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Santen Pharmaceutical Co. Ltd (Japan)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Graybug Vision Inc. (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Clearside Biomedical (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Envisia Therapeutics (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Taiwan Liposome Company (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Ocular Drug Delivery Technology Sale, by Type, Application, Technology, Disease Indication and Region (value) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global Ocular Drug Delivery Technology (Value)
      • 7.2.1. Global Ocular Drug Delivery Technology by: Type (Value)
        • 7.2.1.1. Biodegradable Ocular Drug Delivery Technology
        • 7.2.1.2. Non-Biodegradable Ocular Drug Delivery Technology
      • 7.2.2. Global Ocular Drug Delivery Technology by: Application (Value)
        • 7.2.2.1. Hospitals
        • 7.2.2.2. Ambulatory Surgical Centers
        • 7.2.2.3. Ophthalmic Clinics
        • 7.2.2.4. Homecare Settings
      • 7.2.3. Global Ocular Drug Delivery Technology by: Technology (Value)
        • 7.2.3.1. Topical
        • 7.2.3.2. Iontophoresis
        • 7.2.3.3. Ocular insert
        • 7.2.3.4. Intraocular implants
        • 7.2.3.5. Others
      • 7.2.4. Global Ocular Drug Delivery Technology by: Disease Indication (Value)
        • 7.2.4.1. Cataract Surgery
        • 7.2.4.2. Allergic Conjunctivitis
        • 7.2.4.3. Retinal Vein Occlusion
        • 7.2.4.4. Bulbar Conjunctiva
        • 7.2.4.5. Sympathetic Ophthalmia
        • 7.2.4.6. Others
      • 7.2.5. Global Ocular Drug Delivery Technology Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Ocular Drug Delivery Technology: by Type(USD Million)
  • Table 2. Ocular Drug Delivery Technology Biodegradable Ocular Drug Delivery Technology , by Region USD Million (2015-2020)
  • Table 3. Ocular Drug Delivery Technology Non-Biodegradable Ocular Drug Delivery Technology , by Region USD Million (2015-2020)
  • Table 4. Ocular Drug Delivery Technology: by Application(USD Million)
  • Table 5. Ocular Drug Delivery Technology Hospitals , by Region USD Million (2015-2020)
  • Table 6. Ocular Drug Delivery Technology Ambulatory Surgical Centers , by Region USD Million (2015-2020)
  • Table 7. Ocular Drug Delivery Technology Ophthalmic Clinics , by Region USD Million (2015-2020)
  • Table 8. Ocular Drug Delivery Technology Homecare Settings , by Region USD Million (2015-2020)
  • Table 9. Ocular Drug Delivery Technology: by Technology(USD Million)
  • Table 10. Ocular Drug Delivery Technology Topical , by Region USD Million (2015-2020)
  • Table 11. Ocular Drug Delivery Technology Iontophoresis , by Region USD Million (2015-2020)
  • Table 12. Ocular Drug Delivery Technology Ocular insert , by Region USD Million (2015-2020)
  • Table 13. Ocular Drug Delivery Technology Intraocular implants , by Region USD Million (2015-2020)
  • Table 14. Ocular Drug Delivery Technology Others , by Region USD Million (2015-2020)
  • Table 15. Ocular Drug Delivery Technology: by Disease Indication(USD Million)
  • Table 16. Ocular Drug Delivery Technology Cataract Surgery , by Region USD Million (2015-2020)
  • Table 17. Ocular Drug Delivery Technology Allergic Conjunctivitis , by Region USD Million (2015-2020)
  • Table 18. Ocular Drug Delivery Technology Retinal Vein Occlusion , by Region USD Million (2015-2020)
  • Table 19. Ocular Drug Delivery Technology Bulbar Conjunctiva , by Region USD Million (2015-2020)
  • Table 20. Ocular Drug Delivery Technology Sympathetic Ophthalmia , by Region USD Million (2015-2020)
  • Table 21. Ocular Drug Delivery Technology Others , by Region USD Million (2015-2020)
  • Table 22. South America Ocular Drug Delivery Technology, by Country USD Million (2015-2020)
  • Table 23. South America Ocular Drug Delivery Technology, by Type USD Million (2015-2020)
  • Table 24. South America Ocular Drug Delivery Technology, by Application USD Million (2015-2020)
  • Table 25. South America Ocular Drug Delivery Technology, by Technology USD Million (2015-2020)
  • Table 26. South America Ocular Drug Delivery Technology, by Disease Indication USD Million (2015-2020)
  • Table 27. Brazil Ocular Drug Delivery Technology, by Type USD Million (2015-2020)
  • Table 28. Brazil Ocular Drug Delivery Technology, by Application USD Million (2015-2020)
  • Table 29. Brazil Ocular Drug Delivery Technology, by Technology USD Million (2015-2020)
  • Table 30. Brazil Ocular Drug Delivery Technology, by Disease Indication USD Million (2015-2020)
  • Table 31. Argentina Ocular Drug Delivery Technology, by Type USD Million (2015-2020)
  • Table 32. Argentina Ocular Drug Delivery Technology, by Application USD Million (2015-2020)
  • Table 33. Argentina Ocular Drug Delivery Technology, by Technology USD Million (2015-2020)
  • Table 34. Argentina Ocular Drug Delivery Technology, by Disease Indication USD Million (2015-2020)
  • Table 35. Rest of South America Ocular Drug Delivery Technology, by Type USD Million (2015-2020)
  • Table 36. Rest of South America Ocular Drug Delivery Technology, by Application USD Million (2015-2020)
  • Table 37. Rest of South America Ocular Drug Delivery Technology, by Technology USD Million (2015-2020)
  • Table 38. Rest of South America Ocular Drug Delivery Technology, by Disease Indication USD Million (2015-2020)
  • Table 39. Asia Pacific Ocular Drug Delivery Technology, by Country USD Million (2015-2020)
  • Table 40. Asia Pacific Ocular Drug Delivery Technology, by Type USD Million (2015-2020)
  • Table 41. Asia Pacific Ocular Drug Delivery Technology, by Application USD Million (2015-2020)
  • Table 42. Asia Pacific Ocular Drug Delivery Technology, by Technology USD Million (2015-2020)
  • Table 43. Asia Pacific Ocular Drug Delivery Technology, by Disease Indication USD Million (2015-2020)
  • Table 44. China Ocular Drug Delivery Technology, by Type USD Million (2015-2020)
  • Table 45. China Ocular Drug Delivery Technology, by Application USD Million (2015-2020)
  • Table 46. China Ocular Drug Delivery Technology, by Technology USD Million (2015-2020)
  • Table 47. China Ocular Drug Delivery Technology, by Disease Indication USD Million (2015-2020)
  • Table 48. Japan Ocular Drug Delivery Technology, by Type USD Million (2015-2020)
  • Table 49. Japan Ocular Drug Delivery Technology, by Application USD Million (2015-2020)
  • Table 50. Japan Ocular Drug Delivery Technology, by Technology USD Million (2015-2020)
  • Table 51. Japan Ocular Drug Delivery Technology, by Disease Indication USD Million (2015-2020)
  • Table 52. India Ocular Drug Delivery Technology, by Type USD Million (2015-2020)
  • Table 53. India Ocular Drug Delivery Technology, by Application USD Million (2015-2020)
  • Table 54. India Ocular Drug Delivery Technology, by Technology USD Million (2015-2020)
  • Table 55. India Ocular Drug Delivery Technology, by Disease Indication USD Million (2015-2020)
  • Table 56. South Korea Ocular Drug Delivery Technology, by Type USD Million (2015-2020)
  • Table 57. South Korea Ocular Drug Delivery Technology, by Application USD Million (2015-2020)
  • Table 58. South Korea Ocular Drug Delivery Technology, by Technology USD Million (2015-2020)
  • Table 59. South Korea Ocular Drug Delivery Technology, by Disease Indication USD Million (2015-2020)
  • Table 60. Taiwan Ocular Drug Delivery Technology, by Type USD Million (2015-2020)
  • Table 61. Taiwan Ocular Drug Delivery Technology, by Application USD Million (2015-2020)
  • Table 62. Taiwan Ocular Drug Delivery Technology, by Technology USD Million (2015-2020)
  • Table 63. Taiwan Ocular Drug Delivery Technology, by Disease Indication USD Million (2015-2020)
  • Table 64. Australia Ocular Drug Delivery Technology, by Type USD Million (2015-2020)
  • Table 65. Australia Ocular Drug Delivery Technology, by Application USD Million (2015-2020)
  • Table 66. Australia Ocular Drug Delivery Technology, by Technology USD Million (2015-2020)
  • Table 67. Australia Ocular Drug Delivery Technology, by Disease Indication USD Million (2015-2020)
  • Table 68. Rest of Asia-Pacific Ocular Drug Delivery Technology, by Type USD Million (2015-2020)
  • Table 69. Rest of Asia-Pacific Ocular Drug Delivery Technology, by Application USD Million (2015-2020)
  • Table 70. Rest of Asia-Pacific Ocular Drug Delivery Technology, by Technology USD Million (2015-2020)
  • Table 71. Rest of Asia-Pacific Ocular Drug Delivery Technology, by Disease Indication USD Million (2015-2020)
  • Table 72. Europe Ocular Drug Delivery Technology, by Country USD Million (2015-2020)
  • Table 73. Europe Ocular Drug Delivery Technology, by Type USD Million (2015-2020)
  • Table 74. Europe Ocular Drug Delivery Technology, by Application USD Million (2015-2020)
  • Table 75. Europe Ocular Drug Delivery Technology, by Technology USD Million (2015-2020)
  • Table 76. Europe Ocular Drug Delivery Technology, by Disease Indication USD Million (2015-2020)
  • Table 77. Germany Ocular Drug Delivery Technology, by Type USD Million (2015-2020)
  • Table 78. Germany Ocular Drug Delivery Technology, by Application USD Million (2015-2020)
  • Table 79. Germany Ocular Drug Delivery Technology, by Technology USD Million (2015-2020)
  • Table 80. Germany Ocular Drug Delivery Technology, by Disease Indication USD Million (2015-2020)
  • Table 81. France Ocular Drug Delivery Technology, by Type USD Million (2015-2020)
  • Table 82. France Ocular Drug Delivery Technology, by Application USD Million (2015-2020)
  • Table 83. France Ocular Drug Delivery Technology, by Technology USD Million (2015-2020)
  • Table 84. France Ocular Drug Delivery Technology, by Disease Indication USD Million (2015-2020)
  • Table 85. Italy Ocular Drug Delivery Technology, by Type USD Million (2015-2020)
  • Table 86. Italy Ocular Drug Delivery Technology, by Application USD Million (2015-2020)
  • Table 87. Italy Ocular Drug Delivery Technology, by Technology USD Million (2015-2020)
  • Table 88. Italy Ocular Drug Delivery Technology, by Disease Indication USD Million (2015-2020)
  • Table 89. United Kingdom Ocular Drug Delivery Technology, by Type USD Million (2015-2020)
  • Table 90. United Kingdom Ocular Drug Delivery Technology, by Application USD Million (2015-2020)
  • Table 91. United Kingdom Ocular Drug Delivery Technology, by Technology USD Million (2015-2020)
  • Table 92. United Kingdom Ocular Drug Delivery Technology, by Disease Indication USD Million (2015-2020)
  • Table 93. Netherlands Ocular Drug Delivery Technology, by Type USD Million (2015-2020)
  • Table 94. Netherlands Ocular Drug Delivery Technology, by Application USD Million (2015-2020)
  • Table 95. Netherlands Ocular Drug Delivery Technology, by Technology USD Million (2015-2020)
  • Table 96. Netherlands Ocular Drug Delivery Technology, by Disease Indication USD Million (2015-2020)
  • Table 97. Rest of Europe Ocular Drug Delivery Technology, by Type USD Million (2015-2020)
  • Table 98. Rest of Europe Ocular Drug Delivery Technology, by Application USD Million (2015-2020)
  • Table 99. Rest of Europe Ocular Drug Delivery Technology, by Technology USD Million (2015-2020)
  • Table 100. Rest of Europe Ocular Drug Delivery Technology, by Disease Indication USD Million (2015-2020)
  • Table 101. MEA Ocular Drug Delivery Technology, by Country USD Million (2015-2020)
  • Table 102. MEA Ocular Drug Delivery Technology, by Type USD Million (2015-2020)
  • Table 103. MEA Ocular Drug Delivery Technology, by Application USD Million (2015-2020)
  • Table 104. MEA Ocular Drug Delivery Technology, by Technology USD Million (2015-2020)
  • Table 105. MEA Ocular Drug Delivery Technology, by Disease Indication USD Million (2015-2020)
  • Table 106. Middle East Ocular Drug Delivery Technology, by Type USD Million (2015-2020)
  • Table 107. Middle East Ocular Drug Delivery Technology, by Application USD Million (2015-2020)
  • Table 108. Middle East Ocular Drug Delivery Technology, by Technology USD Million (2015-2020)
  • Table 109. Middle East Ocular Drug Delivery Technology, by Disease Indication USD Million (2015-2020)
  • Table 110. Africa Ocular Drug Delivery Technology, by Type USD Million (2015-2020)
  • Table 111. Africa Ocular Drug Delivery Technology, by Application USD Million (2015-2020)
  • Table 112. Africa Ocular Drug Delivery Technology, by Technology USD Million (2015-2020)
  • Table 113. Africa Ocular Drug Delivery Technology, by Disease Indication USD Million (2015-2020)
  • Table 114. North America Ocular Drug Delivery Technology, by Country USD Million (2015-2020)
  • Table 115. North America Ocular Drug Delivery Technology, by Type USD Million (2015-2020)
  • Table 116. North America Ocular Drug Delivery Technology, by Application USD Million (2015-2020)
  • Table 117. North America Ocular Drug Delivery Technology, by Technology USD Million (2015-2020)
  • Table 118. North America Ocular Drug Delivery Technology, by Disease Indication USD Million (2015-2020)
  • Table 119. United States Ocular Drug Delivery Technology, by Type USD Million (2015-2020)
  • Table 120. United States Ocular Drug Delivery Technology, by Application USD Million (2015-2020)
  • Table 121. United States Ocular Drug Delivery Technology, by Technology USD Million (2015-2020)
  • Table 122. United States Ocular Drug Delivery Technology, by Disease Indication USD Million (2015-2020)
  • Table 123. Canada Ocular Drug Delivery Technology, by Type USD Million (2015-2020)
  • Table 124. Canada Ocular Drug Delivery Technology, by Application USD Million (2015-2020)
  • Table 125. Canada Ocular Drug Delivery Technology, by Technology USD Million (2015-2020)
  • Table 126. Canada Ocular Drug Delivery Technology, by Disease Indication USD Million (2015-2020)
  • Table 127. Mexico Ocular Drug Delivery Technology, by Type USD Million (2015-2020)
  • Table 128. Mexico Ocular Drug Delivery Technology, by Application USD Million (2015-2020)
  • Table 129. Mexico Ocular Drug Delivery Technology, by Technology USD Million (2015-2020)
  • Table 130. Mexico Ocular Drug Delivery Technology, by Disease Indication USD Million (2015-2020)
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Company Basic Information, Sales Area and Its Competitors
  • Table 140. Company Basic Information, Sales Area and Its Competitors
  • Table 141. Ocular Drug Delivery Technology: by Type(USD Million)
  • Table 142. Ocular Drug Delivery Technology Biodegradable Ocular Drug Delivery Technology , by Region USD Million (2021-2026)
  • Table 143. Ocular Drug Delivery Technology Non-Biodegradable Ocular Drug Delivery Technology , by Region USD Million (2021-2026)
  • Table 144. Ocular Drug Delivery Technology: by Application(USD Million)
  • Table 145. Ocular Drug Delivery Technology Hospitals , by Region USD Million (2021-2026)
  • Table 146. Ocular Drug Delivery Technology Ambulatory Surgical Centers , by Region USD Million (2021-2026)
  • Table 147. Ocular Drug Delivery Technology Ophthalmic Clinics , by Region USD Million (2021-2026)
  • Table 148. Ocular Drug Delivery Technology Homecare Settings , by Region USD Million (2021-2026)
  • Table 149. Ocular Drug Delivery Technology: by Technology(USD Million)
  • Table 150. Ocular Drug Delivery Technology Topical , by Region USD Million (2021-2026)
  • Table 151. Ocular Drug Delivery Technology Iontophoresis , by Region USD Million (2021-2026)
  • Table 152. Ocular Drug Delivery Technology Ocular insert , by Region USD Million (2021-2026)
  • Table 153. Ocular Drug Delivery Technology Intraocular implants , by Region USD Million (2021-2026)
  • Table 154. Ocular Drug Delivery Technology Others , by Region USD Million (2021-2026)
  • Table 155. Ocular Drug Delivery Technology: by Disease Indication(USD Million)
  • Table 156. Ocular Drug Delivery Technology Cataract Surgery , by Region USD Million (2021-2026)
  • Table 157. Ocular Drug Delivery Technology Allergic Conjunctivitis , by Region USD Million (2021-2026)
  • Table 158. Ocular Drug Delivery Technology Retinal Vein Occlusion , by Region USD Million (2021-2026)
  • Table 159. Ocular Drug Delivery Technology Bulbar Conjunctiva , by Region USD Million (2021-2026)
  • Table 160. Ocular Drug Delivery Technology Sympathetic Ophthalmia , by Region USD Million (2021-2026)
  • Table 161. Ocular Drug Delivery Technology Others , by Region USD Million (2021-2026)
  • Table 162. South America Ocular Drug Delivery Technology, by Country USD Million (2021-2026)
  • Table 163. South America Ocular Drug Delivery Technology, by Type USD Million (2021-2026)
  • Table 164. South America Ocular Drug Delivery Technology, by Application USD Million (2021-2026)
  • Table 165. South America Ocular Drug Delivery Technology, by Technology USD Million (2021-2026)
  • Table 166. South America Ocular Drug Delivery Technology, by Disease Indication USD Million (2021-2026)
  • Table 167. Brazil Ocular Drug Delivery Technology, by Type USD Million (2021-2026)
  • Table 168. Brazil Ocular Drug Delivery Technology, by Application USD Million (2021-2026)
  • Table 169. Brazil Ocular Drug Delivery Technology, by Technology USD Million (2021-2026)
  • Table 170. Brazil Ocular Drug Delivery Technology, by Disease Indication USD Million (2021-2026)
  • Table 171. Argentina Ocular Drug Delivery Technology, by Type USD Million (2021-2026)
  • Table 172. Argentina Ocular Drug Delivery Technology, by Application USD Million (2021-2026)
  • Table 173. Argentina Ocular Drug Delivery Technology, by Technology USD Million (2021-2026)
  • Table 174. Argentina Ocular Drug Delivery Technology, by Disease Indication USD Million (2021-2026)
  • Table 175. Rest of South America Ocular Drug Delivery Technology, by Type USD Million (2021-2026)
  • Table 176. Rest of South America Ocular Drug Delivery Technology, by Application USD Million (2021-2026)
  • Table 177. Rest of South America Ocular Drug Delivery Technology, by Technology USD Million (2021-2026)
  • Table 178. Rest of South America Ocular Drug Delivery Technology, by Disease Indication USD Million (2021-2026)
  • Table 179. Asia Pacific Ocular Drug Delivery Technology, by Country USD Million (2021-2026)
  • Table 180. Asia Pacific Ocular Drug Delivery Technology, by Type USD Million (2021-2026)
  • Table 181. Asia Pacific Ocular Drug Delivery Technology, by Application USD Million (2021-2026)
  • Table 182. Asia Pacific Ocular Drug Delivery Technology, by Technology USD Million (2021-2026)
  • Table 183. Asia Pacific Ocular Drug Delivery Technology, by Disease Indication USD Million (2021-2026)
  • Table 184. China Ocular Drug Delivery Technology, by Type USD Million (2021-2026)
  • Table 185. China Ocular Drug Delivery Technology, by Application USD Million (2021-2026)
  • Table 186. China Ocular Drug Delivery Technology, by Technology USD Million (2021-2026)
  • Table 187. China Ocular Drug Delivery Technology, by Disease Indication USD Million (2021-2026)
  • Table 188. Japan Ocular Drug Delivery Technology, by Type USD Million (2021-2026)
  • Table 189. Japan Ocular Drug Delivery Technology, by Application USD Million (2021-2026)
  • Table 190. Japan Ocular Drug Delivery Technology, by Technology USD Million (2021-2026)
  • Table 191. Japan Ocular Drug Delivery Technology, by Disease Indication USD Million (2021-2026)
  • Table 192. India Ocular Drug Delivery Technology, by Type USD Million (2021-2026)
  • Table 193. India Ocular Drug Delivery Technology, by Application USD Million (2021-2026)
  • Table 194. India Ocular Drug Delivery Technology, by Technology USD Million (2021-2026)
  • Table 195. India Ocular Drug Delivery Technology, by Disease Indication USD Million (2021-2026)
  • Table 196. South Korea Ocular Drug Delivery Technology, by Type USD Million (2021-2026)
  • Table 197. South Korea Ocular Drug Delivery Technology, by Application USD Million (2021-2026)
  • Table 198. South Korea Ocular Drug Delivery Technology, by Technology USD Million (2021-2026)
  • Table 199. South Korea Ocular Drug Delivery Technology, by Disease Indication USD Million (2021-2026)
  • Table 200. Taiwan Ocular Drug Delivery Technology, by Type USD Million (2021-2026)
  • Table 201. Taiwan Ocular Drug Delivery Technology, by Application USD Million (2021-2026)
  • Table 202. Taiwan Ocular Drug Delivery Technology, by Technology USD Million (2021-2026)
  • Table 203. Taiwan Ocular Drug Delivery Technology, by Disease Indication USD Million (2021-2026)
  • Table 204. Australia Ocular Drug Delivery Technology, by Type USD Million (2021-2026)
  • Table 205. Australia Ocular Drug Delivery Technology, by Application USD Million (2021-2026)
  • Table 206. Australia Ocular Drug Delivery Technology, by Technology USD Million (2021-2026)
  • Table 207. Australia Ocular Drug Delivery Technology, by Disease Indication USD Million (2021-2026)
  • Table 208. Rest of Asia-Pacific Ocular Drug Delivery Technology, by Type USD Million (2021-2026)
  • Table 209. Rest of Asia-Pacific Ocular Drug Delivery Technology, by Application USD Million (2021-2026)
  • Table 210. Rest of Asia-Pacific Ocular Drug Delivery Technology, by Technology USD Million (2021-2026)
  • Table 211. Rest of Asia-Pacific Ocular Drug Delivery Technology, by Disease Indication USD Million (2021-2026)
  • Table 212. Europe Ocular Drug Delivery Technology, by Country USD Million (2021-2026)
  • Table 213. Europe Ocular Drug Delivery Technology, by Type USD Million (2021-2026)
  • Table 214. Europe Ocular Drug Delivery Technology, by Application USD Million (2021-2026)
  • Table 215. Europe Ocular Drug Delivery Technology, by Technology USD Million (2021-2026)
  • Table 216. Europe Ocular Drug Delivery Technology, by Disease Indication USD Million (2021-2026)
  • Table 217. Germany Ocular Drug Delivery Technology, by Type USD Million (2021-2026)
  • Table 218. Germany Ocular Drug Delivery Technology, by Application USD Million (2021-2026)
  • Table 219. Germany Ocular Drug Delivery Technology, by Technology USD Million (2021-2026)
  • Table 220. Germany Ocular Drug Delivery Technology, by Disease Indication USD Million (2021-2026)
  • Table 221. France Ocular Drug Delivery Technology, by Type USD Million (2021-2026)
  • Table 222. France Ocular Drug Delivery Technology, by Application USD Million (2021-2026)
  • Table 223. France Ocular Drug Delivery Technology, by Technology USD Million (2021-2026)
  • Table 224. France Ocular Drug Delivery Technology, by Disease Indication USD Million (2021-2026)
  • Table 225. Italy Ocular Drug Delivery Technology, by Type USD Million (2021-2026)
  • Table 226. Italy Ocular Drug Delivery Technology, by Application USD Million (2021-2026)
  • Table 227. Italy Ocular Drug Delivery Technology, by Technology USD Million (2021-2026)
  • Table 228. Italy Ocular Drug Delivery Technology, by Disease Indication USD Million (2021-2026)
  • Table 229. United Kingdom Ocular Drug Delivery Technology, by Type USD Million (2021-2026)
  • Table 230. United Kingdom Ocular Drug Delivery Technology, by Application USD Million (2021-2026)
  • Table 231. United Kingdom Ocular Drug Delivery Technology, by Technology USD Million (2021-2026)
  • Table 232. United Kingdom Ocular Drug Delivery Technology, by Disease Indication USD Million (2021-2026)
  • Table 233. Netherlands Ocular Drug Delivery Technology, by Type USD Million (2021-2026)
  • Table 234. Netherlands Ocular Drug Delivery Technology, by Application USD Million (2021-2026)
  • Table 235. Netherlands Ocular Drug Delivery Technology, by Technology USD Million (2021-2026)
  • Table 236. Netherlands Ocular Drug Delivery Technology, by Disease Indication USD Million (2021-2026)
  • Table 237. Rest of Europe Ocular Drug Delivery Technology, by Type USD Million (2021-2026)
  • Table 238. Rest of Europe Ocular Drug Delivery Technology, by Application USD Million (2021-2026)
  • Table 239. Rest of Europe Ocular Drug Delivery Technology, by Technology USD Million (2021-2026)
  • Table 240. Rest of Europe Ocular Drug Delivery Technology, by Disease Indication USD Million (2021-2026)
  • Table 241. MEA Ocular Drug Delivery Technology, by Country USD Million (2021-2026)
  • Table 242. MEA Ocular Drug Delivery Technology, by Type USD Million (2021-2026)
  • Table 243. MEA Ocular Drug Delivery Technology, by Application USD Million (2021-2026)
  • Table 244. MEA Ocular Drug Delivery Technology, by Technology USD Million (2021-2026)
  • Table 245. MEA Ocular Drug Delivery Technology, by Disease Indication USD Million (2021-2026)
  • Table 246. Middle East Ocular Drug Delivery Technology, by Type USD Million (2021-2026)
  • Table 247. Middle East Ocular Drug Delivery Technology, by Application USD Million (2021-2026)
  • Table 248. Middle East Ocular Drug Delivery Technology, by Technology USD Million (2021-2026)
  • Table 249. Middle East Ocular Drug Delivery Technology, by Disease Indication USD Million (2021-2026)
  • Table 250. Africa Ocular Drug Delivery Technology, by Type USD Million (2021-2026)
  • Table 251. Africa Ocular Drug Delivery Technology, by Application USD Million (2021-2026)
  • Table 252. Africa Ocular Drug Delivery Technology, by Technology USD Million (2021-2026)
  • Table 253. Africa Ocular Drug Delivery Technology, by Disease Indication USD Million (2021-2026)
  • Table 254. North America Ocular Drug Delivery Technology, by Country USD Million (2021-2026)
  • Table 255. North America Ocular Drug Delivery Technology, by Type USD Million (2021-2026)
  • Table 256. North America Ocular Drug Delivery Technology, by Application USD Million (2021-2026)
  • Table 257. North America Ocular Drug Delivery Technology, by Technology USD Million (2021-2026)
  • Table 258. North America Ocular Drug Delivery Technology, by Disease Indication USD Million (2021-2026)
  • Table 259. United States Ocular Drug Delivery Technology, by Type USD Million (2021-2026)
  • Table 260. United States Ocular Drug Delivery Technology, by Application USD Million (2021-2026)
  • Table 261. United States Ocular Drug Delivery Technology, by Technology USD Million (2021-2026)
  • Table 262. United States Ocular Drug Delivery Technology, by Disease Indication USD Million (2021-2026)
  • Table 263. Canada Ocular Drug Delivery Technology, by Type USD Million (2021-2026)
  • Table 264. Canada Ocular Drug Delivery Technology, by Application USD Million (2021-2026)
  • Table 265. Canada Ocular Drug Delivery Technology, by Technology USD Million (2021-2026)
  • Table 266. Canada Ocular Drug Delivery Technology, by Disease Indication USD Million (2021-2026)
  • Table 267. Mexico Ocular Drug Delivery Technology, by Type USD Million (2021-2026)
  • Table 268. Mexico Ocular Drug Delivery Technology, by Application USD Million (2021-2026)
  • Table 269. Mexico Ocular Drug Delivery Technology, by Technology USD Million (2021-2026)
  • Table 270. Mexico Ocular Drug Delivery Technology, by Disease Indication USD Million (2021-2026)
  • Table 271. Research Programs/Design for This Report
  • Table 272. Key Data Information from Secondary Sources
  • Table 273. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Ocular Drug Delivery Technology: by Type USD Million (2015-2020)
  • Figure 5. Global Ocular Drug Delivery Technology: by Application USD Million (2015-2020)
  • Figure 6. Global Ocular Drug Delivery Technology: by Technology USD Million (2015-2020)
  • Figure 7. Global Ocular Drug Delivery Technology: by Disease Indication USD Million (2015-2020)
  • Figure 8. South America Ocular Drug Delivery Technology Share (%), by Country
  • Figure 9. Asia Pacific Ocular Drug Delivery Technology Share (%), by Country
  • Figure 10. Europe Ocular Drug Delivery Technology Share (%), by Country
  • Figure 11. MEA Ocular Drug Delivery Technology Share (%), by Country
  • Figure 12. North America Ocular Drug Delivery Technology Share (%), by Country
  • Figure 13. Global Ocular Drug Delivery Technology share by Players 2020 (%)
  • Figure 14. Global Ocular Drug Delivery Technology share by Players (Top 3) 2020(%)
  • Figure 15. Global Ocular Drug Delivery Technology share by Players (Top 5) 2020(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Ocular Therapeutix, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 18. Ocular Therapeutix, Inc. (United States) Revenue: by Geography 2020
  • Figure 19. Alimera Sciences (United States) Revenue, Net Income and Gross profit
  • Figure 20. Alimera Sciences (United States) Revenue: by Geography 2020
  • Figure 21. Allergan plc (Ireland) Revenue, Net Income and Gross profit
  • Figure 22. Allergan plc (Ireland) Revenue: by Geography 2020
  • Figure 23. Bausch Health Cos. (United States) Revenue, Net Income and Gross profit
  • Figure 24. Bausch Health Cos. (United States) Revenue: by Geography 2020
  • Figure 25. EyeGate Pharma (United States) Revenue, Net Income and Gross profit
  • Figure 26. EyeGate Pharma (United States) Revenue: by Geography 2020
  • Figure 27. Santen Pharmaceutical Co. Ltd (Japan) Revenue, Net Income and Gross profit
  • Figure 28. Santen Pharmaceutical Co. Ltd (Japan) Revenue: by Geography 2020
  • Figure 29. Graybug Vision Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 30. Graybug Vision Inc. (United States) Revenue: by Geography 2020
  • Figure 31. Clearside Biomedical (United States) Revenue, Net Income and Gross profit
  • Figure 32. Clearside Biomedical (United States) Revenue: by Geography 2020
  • Figure 33. Envisia Therapeutics (United States) Revenue, Net Income and Gross profit
  • Figure 34. Envisia Therapeutics (United States) Revenue: by Geography 2020
  • Figure 35. Taiwan Liposome Company (United States) Revenue, Net Income and Gross profit
  • Figure 36. Taiwan Liposome Company (United States) Revenue: by Geography 2020
  • Figure 37. Global Ocular Drug Delivery Technology: by Type USD Million (2021-2026)
  • Figure 38. Global Ocular Drug Delivery Technology: by Application USD Million (2021-2026)
  • Figure 39. Global Ocular Drug Delivery Technology: by Technology USD Million (2021-2026)
  • Figure 40. Global Ocular Drug Delivery Technology: by Disease Indication USD Million (2021-2026)
  • Figure 41. South America Ocular Drug Delivery Technology Share (%), by Country
  • Figure 42. Asia Pacific Ocular Drug Delivery Technology Share (%), by Country
  • Figure 43. Europe Ocular Drug Delivery Technology Share (%), by Country
  • Figure 44. MEA Ocular Drug Delivery Technology Share (%), by Country
  • Figure 45. North America Ocular Drug Delivery Technology Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Ocular Therapeutix, Inc. (United States)
  • Alimera Sciences (United States)
  • Allergan plc (Ireland)
  • Bausch Health Cos. (United States)
  • EyeGate Pharma (United States)
  • Santen Pharmaceutical Co. Ltd (Japan)
  • Graybug Vision Inc. (United States)
  • Clearside Biomedical (United States)
  • Envisia Therapeutics (United States)
  • Taiwan Liposome Company (United States)
Select User Access Type

Key Highlights of Report


Mar 2021 217 Pages 78 Tables Base Year: 2021 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Ocular Drug Delivery Technology Quantitative research analysis
Global Ocular Drug Delivery Technology Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Know More About Global Ocular Drug Delivery Technology Report?

Have a Query? Click Here

Other Related Reports

Cell Separation Comprehensive Study by Type (Gradient centrifugation , Surface markers separation, Fluorescence activated cell sorting, Magnetic cell sorting), Application (Oncology research, Neurosc...
$ 3750
Bionic Devices Comprehensive Study by Type (Cochlear Implants, Exoskeletons, Cardiac Bionics, Ventricular Assist Device), Application (Hospital, Clinic, Others), Fixation (Implantable bionics, Extern...
$ 3350
Orthopedic Navigation System Comprehensive Study by Application (Hip Replacement Surgery, Knee Replacement Surgery, Shoulder and Rotator Cuff Surgery), End Users (Hospitals, Specialized Clinics, Ambu...
$ 3750
3D Medical Imaging Comprehensive Study by Application (Oncology, Cardiology, Orthopedic, Others), Distribution Channel (Online Retail, Offline Retail), Technique (Ultrasound, X-Ray, CT scan, MRI, H...
$ 3450
Smart Healthcare Products Comprehensive Study by Type (Telemedicine, Electronic Health Records, MHealth, Smart Pills and Syringes, Smart RFID Cabinets, Other), Application (Storage and Inventory Mana...
$ 3450
ECG Analysis System Comprehensive Study by Type (Single-Channel, Three Channel, Six Channel, Twelve Channel), Application (Hospital, Clinics, Home, Clinic) Players and Region - Global Market Outlook ...
$ 3500